This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Checking in with a prescriber of Amylyx's Relyvrio for the slowing of ALS progression.
Ticker(s): AMLXWho's the expert?
Institution: University of Buffalo
- Clinical Associate Professor of Neurology at the University of Buffalo.
- Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
- Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.
Interview GoalThis call will discuss the current standard of care and the use of Amylyx's Relyvrio (sodium phenylbutyrate and taurursodiol) for the slowing of disease progression in patients with ALS. The call will also focus on the expert's prescribing patterns and impression of Relyvrio so far in their patients.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
